| 000 | 00981nam a2200325Ia 4500 | ||
|---|---|---|---|
| 003 | OSt | ||
| 005 | 20220912144012.0 | ||
| 006 | a|||||r|||| 00| 0 | ||
| 007 | ta | ||
| 008 | 220909b |||||||| |||| 00| 0 eng d | ||
| 020 | _a9781498709552 (hbk) | ||
| 024 | _a197188 | ||
| 037 | _b14, 17/04/2017, Aviva Books Company | ||
| 037 | _cTextual | ||
| 040 | _beng | ||
| 041 | _aeng | ||
| 082 | _aB2871, Q6 | ||
| 100 | _aYuan Ying | ||
| 245 | 0 | _aBayesian designs for phase I-II clinical trials | |
| 260 |
_aBoca Raton _bCRC Press _c2016 |
||
| 300 |
_axiv,310p. ill. _ccm |
||
| 500 | _aBibliography 283-300p.; Index 301-310p. | ||
| 650 | _a Optimizing doses in two Cycles | ||
| 650 | _a Personalized dose finding | ||
| 650 | _aEstablishing Priors | ||
| 700 | _a Nguyen Hoang Q. | ||
| 700 | _a Thall Peter F. | ||
| 942 |
_hB2871, Q6 _cTEXL _2CC |
||
| 999 |
_c582 _d582 |
||